HCQ history in this paper:
Hydroxychloroquine: From Malaria to Autoimmunity
Ilan Ben-Zvi, Shaye Kivity, Pnina Langevitz, Yehuda Shoenfeld
Clin Rev Allergy Immunol. 2012; 42(2): 145–153. Published online 2011 Jan 8. doi: 10.1007/s12016-010-8243-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091063/
Table 1: Traditional indications and doses for the use of hydroxychloroquine
Table 2: Main adverse effects of chloroquine and HCQ treatment
Table 3: A summary of the effects of antimalarials in various conditions
Abstract: Quinine was first recognized as a potent antimalarial agent hundreds of years ago. Since then, the beneficial effects of quinine and its more advanced synthetic forms, chloroquine and hydroxychloroquine, have been increasingly recognized in a myriad of other diseases in addition to malaria. In recent years, antimalarials were shown to have various immunomodulatory effects, and currently have an established role in the management of rheumatic diseases, such as systemic lupus erythematosus and rheumatoid arthritis, skin diseases, and in the treatment of chronic Q fever. Lately, additional metabolic, cardiovascular, antithrombotic, and antineoplastic effects of antimalarials were shown. In this review, we discuss the known various immunomodulatory mechanisms of antimalarials and the current evidence for their beneficial effects in various diseases and in potential novel applications.
Keywords: Chloroquine, Hydroxychloroquine, Antimalarial, Novel, Therapy, Lupus"
Also,
Here is an Apr.9 review of ongoing clinical trials:
"Ongoing Clinical Trials for the Management of the COVID-19 Pandemic"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144665/
"Thirty-five trials are now investigating the use of the antimalarial drugs chloroquine and hydroxychloroquine against COVID-19 (Table 1A: Antimalarials)… Table 1. Ongoing Clinical Trials for the (A) Treatment and (B) Prevention of COVID-19 (Current as of 20 March, 2020)"